This HTML5 document contains 19 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

PrefixNamespace IRI
vivohttp://vivoweb.org/ontology/core#
dctermshttp://purl.org/dc/terms/
n4http://hub.abes.fr/bmj/periodical/adc/2000/volume_82/issue_4/B35305B433FB0CF1E053120B220A6A4C/subject/
n9http://hub.abes.fr/bmj/periodical/adc/2000/volume_82/issue_4/B35305B433FB0CF1E053120B220A6A4C/authorship/
n12http://hub.abes.fr/referentiel/bmjarticlecategories/subject/
n2http://hub.abes.fr/bmj/periodical/adc/2000/volume_82/issue_4/B35305B433FB0CF1E053120B220A6A4C/
n16http://hub.abes.fr/bmj/periodical/adc/
bibohttp://purl.org/ontology/bibo/
rdachttp://rdaregistry.info/Elements/c/
n7http://hub.abes.fr/bmj/periodical/adc/2000/volume_82/issue_4/
hubhttp://hub.abes.fr/namespace/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n15http://hub.abes.fr/bmj/periodical/articletype/
rdawhttp://rdaregistry.info/Elements/w/
n10http://hub.abes.fr/referentiel/hwpjournalcoll/subject/
xsdhhttp://www.w3.org/2001/XMLSchema#
n6http://hub.abes.fr/bmj/periodical/adc/2000/volume_82/issue_4/B35305B433FB0CF1E053120B220A6A4C/m/
Subject Item
n2:w
rdf:type
rdac:C10001 bibo:Article
dcterms:isPartOf
n7:w
dcterms:subject
n4:lymphangioma n4:ok432 n10:oncology n12:article
dcterms:title
Sclerosing treatment of lymphangiomas with OK-432
rdaw:P10072
n6:web n6:print
vivo:relatedBy
n9:4 n9:2 n9:3 n9:1
dcterms:abstract
Over a period of seven years, 15 patients (aged from birth to 15 years; median 22 months) with lymphangioma were treated with OK-432; they received a mean of three injections each. Ten received OK-432 as first line treatment; five were treated after surgery (three had a residual lymphangioma after incomplete removal and two had a late recurrence). OK-432 proved to be effective for primitive as well as for residual and recurrent lymphangioma. Seven cases were macrocystic; complete regression was obtained in all. Five cases were microcystic: two had more than 50% regression, and three less than 50%. Three cases were mixed, with both large and microscopic cysts: one had more than 50% regression, and two less than 50%. These last two cases underwent surgery after the sclerosing treatment. The results obtained were excellent in 100% of macrocystic cases; a shrinkage in size was obtained in all microcystic cases. OK-432 is therefore proposed as a first line option for treatment of lymphangiomas.
hub:articleType
n15:researcharticle
hub:publisher-id
99642
hub:isPartOfThisJournal
n16:w
bibo:pmid
10735841